Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($7.75) per share for the quarter.
Aptevo Therapeutics Stock Down 7.5 %
APVO stock opened at $3.21 on Tuesday. The stock’s 50 day simple moving average is $4.33 and its 200 day simple moving average is $222.04. Aptevo Therapeutics has a fifty-two week low of $3.01 and a fifty-two week high of $399.60.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a report on Monday, December 9th. They issued a “sell” rating on the stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Articles
- Five stocks we like better than Aptevo Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Finding Hidden Gems: Unconventional Penny Stock Investing
- 3 Small Caps With Big Return Potential
- Price Targets on NVIDIA Rise in Front of Earnings
- Bank Stocks – Best Bank Stocks to Invest In
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
